A bit more time for castration-resistant prostate cancer victims
A study published today in The Lancet by Dr. Fred Saad of the University of Montreal and Dr. Mathew R. Smith of the Massachusetts General Hospital Cancer Center reveals that the drug denosumab inhibits the bone metastasis of prostate cancer. The researchers worked with 1432 men suffering from a castration resistant prostate cancer and found that the bone-metastasis-free survival of those receiving the drug increasing by a median of 4·2 months compared to the control group. Overall survival did not differ between groups. Bone metastases are a major cause of morbidity and mortality in men with prostate cancer.
Dr. Fred Saad is available to speak with the media about this study and prostate cancer generally. To set up an interview or to obtain a copy of the study, please contact William Raillant-Clark, University of Montreal, at 514-343-7593 or w.raillant-clark@umontreal.ca
Image: Prostate et organes environnants (coupe sagitale pour la seconde illustration). National Institutes of Health.
